Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FATENASDAQ:GLSINYSE:IKTNASDAQ:LVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFATEFate Therapeutics$1.28-8.9%$1.20$0.66▼$5.92$146.12M2.232.25 million shs2.43 million shsGLSIGreenwich LifeSciences$9.20-2.9%$9.63$8.06▼$18.75$122.99M1.6946,730 shs23,025 shsIKTInhibikase Therapeutics$1.86-2.6%$2.00$1.12▼$4.20$138.28M0.94239,591 shs92,001 shsLVTXLAVA Therapeutics$1.31$1.27$0.85▼$2.39$34.46M0.48157,856 shs6,986 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFATEFate Therapeutics0.00%-20.31%+26.24%+35.42%-66.18%GLSIGreenwich LifeSciences0.00%-4.76%-5.06%-23.33%-35.66%IKTInhibikase Therapeutics0.00%-5.10%-8.37%-17.33%+17.72%LVTXLAVA Therapeutics0.00%-0.76%+3.97%+0.77%-42.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFATEFate Therapeutics4.0819 of 5 stars3.13.00.04.72.61.70.6GLSIGreenwich LifeSciences2.2356 of 5 stars3.51.00.00.02.73.30.0IKTInhibikase Therapeutics1.4582 of 5 stars3.31.00.00.02.60.00.6LVTXLAVA Therapeutics2.1992 of 5 stars3.05.00.00.02.20.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFATEFate Therapeutics 2.22Hold$4.14224.93% UpsideGLSIGreenwich LifeSciences 3.00Buy$39.00323.91% UpsideIKTInhibikase Therapeutics 2.50Moderate Buy$6.50249.46% UpsideLVTXLAVA Therapeutics 2.00Hold$3.17141.73% UpsideCurrent Analyst Ratings BreakdownLatest LVTX, FATE, IKT, and GLSI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/15/2025LVTXLAVA TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/14/2025FATEFate TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$10.00 ➝ $2.005/14/2025FATEFate TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$5.00 ➝ $4.005/14/2025FATEFate TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold4/21/2025GLSIGreenwich LifeSciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$38.00 ➝ $39.003/31/2025LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$1.50 ➝ $1.503/28/2025IKTInhibikase TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFATEFate Therapeutics$13.34M10.96N/AN/A$3.74 per share0.34GLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.52 per shareN/AIKTInhibikase Therapeutics$260K531.83N/AN/A$1.78 per share1.04LVTXLAVA Therapeutics$4.99M6.91N/AN/A$1.95 per share0.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFATEFate Therapeutics-$160.93M-$1.49N/AN/AN/A-1,325.43%-45.88%-33.95%8/12/2025 (Estimated)GLSIGreenwich LifeSciences-$8.89M-$1.26N/AN/AN/AN/A-185.12%-164.27%8/12/2025 (Estimated)IKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/ALVTXLAVA Therapeutics-$41.97M-$1.04N/AN/AN/AN/A-62.22%-29.37%8/19/2025 (Estimated)Latest LVTX, FATE, IKT, and GLSI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025GLSIGreenwich LifeSciences-$0.24-$0.25-$0.01-$0.25N/AN/A5/14/2025Q1 2025LVTXLAVA Therapeutics-$0.37-$0.13+$0.24-$0.13N/AN/A5/13/2025Q1 2025FATEFate Therapeutics-$0.39-$0.32+$0.07-$0.32$1.18 million$1.63 million4/15/2025Q4 2024GLSIGreenwich LifeSciences-$0.21-$0.61-$0.40-$0.61N/AN/A3/28/2025Q4 2024LVTXLAVA Therapeutics-$0.32-$0.14+$0.18-$0.14$2.40 million$2.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFATEFate TherapeuticsN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFATEFate TherapeuticsN/A8.298.29GLSIGreenwich LifeSciencesN/A6.916.91IKTInhibikase TherapeuticsN/A0.850.85LVTXLAVA TherapeuticsN/A5.365.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFATEFate Therapeutics97.54%GLSIGreenwich LifeSciences4.16%IKTInhibikase Therapeutics3.81%LVTXLAVA TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipFATEFate Therapeutics5.51%GLSIGreenwich LifeSciences51.67%IKTInhibikase Therapeutics7.30%LVTXLAVA Therapeutics9.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFATEFate Therapeutics550114.60 million108.20 millionOptionableGLSIGreenwich LifeSciences313.37 million6.35 millionNot OptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionableLVTXLAVA Therapeutics6026.31 million26.08 millionOptionableLVTX, FATE, IKT, and GLSI HeadlinesRecent News About These CompaniesLAVA Therapeutics Shareholders Approve Key Proposals in MeetingJune 13 at 5:13 PM | tipranks.comHere's Why We're Watching LAVA Therapeutics' (NASDAQ:LVTX) Cash Burn SituationMay 16, 2025 | finance.yahoo.comLAVA Therapeutics N.V.: LAVA Reports First Quarter 2025 Financial Results, Provides Business UpdateMay 15, 2025 | finanznachrichten.deLAVA Reports First Quarter 2025 Financial Results, Provides Business UpdateMay 14, 2025 | globenewswire.comLAVA Therapeutics Granted Full Waiver for RVO Payment Obligation | LVTX Stock NewsApril 16, 2025 | gurufocus.comLAVA Therapeutics Strengthens Balance Sheet with $5.1 Million Repayment Waiver from Netherlands Enterprise AgencyApril 16, 2025 | quiverquant.comLAVA Therapeutics (LVTX) Secures $5.1 Million Debt Waiver from Netherlands Enterprise Agency | ...April 16, 2025 | gurufocus.comLAVA Therapeutics Granted Full Waiver for RVO Payment ObligationApril 16, 2025 | globenewswire.comLava Therapeutics reports Q4 EPS (14c) vs. (24c) last yearMarch 29, 2025 | markets.businessinsider.comLAVA Therapeutics GAAP EPS of -$0.14, revenue of $4.99MMarch 28, 2025 | seekingalpha.comLAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateMarch 28, 2025 | globenewswire.comAnalyst Downgrades LAVA Therapeutics, Sees Pipeline OverhangFebruary 28, 2025 | benzinga.comCautious Stance on LAVA Therapeutics Amid Strategic Review and Workforce ReductionFebruary 27, 2025 | tipranks.comLava Therapeutics announces evaluation of strategic optionsFebruary 26, 2025 | markets.businessinsider.comLAVA Therapeutics (NASDAQ:LVTX) Stock Quotes, Forecast and News SummaryFebruary 26, 2025 | benzinga.comLava Therapeutics trims workforce by 30% to preserve cashFebruary 25, 2025 | bizjournals.comSerina Therapeutics Appoints Karen J. Wilson to Board of DirectorsJanuary 14, 2025 | quiverquant.comLAVA Therapeutics Doses First Patient in Phase 1 Study of Bispecific Gammabody® LAVA-1266 for CD123-Expressing Blood CancersJanuary 10, 2025 | quiverquant.comLAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological CancersJanuary 10, 2025 | globenewswire.comLAVA Therapeutics to Transition to U.S. Domestic IssuerJanuary 2, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsIn a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockBy Leo Miller | June 9, 2025View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback StockLVTX, FATE, IKT, and GLSI Company DescriptionsFate Therapeutics NASDAQ:FATE$1.27 -0.13 (-8.93%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.28 +0.00 (+0.08%) As of 06/13/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.Greenwich LifeSciences NASDAQ:GLSI$9.20 -0.27 (-2.85%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$9.23 +0.03 (+0.33%) As of 06/13/2025 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Inhibikase Therapeutics NYSE:IKT$1.87 -0.04 (-2.09%) As of 06/13/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.LAVA Therapeutics NASDAQ:LVTX$1.31 0.00 (0.00%) Closing price 06/13/2025 03:58 PM EasternExtended Trading$1.30 -0.01 (-0.76%) As of 06/13/2025 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
